F. Submission and Deadline

Submit the original and two copies of the application including the PHS Form 5161–1 (OMB Number 0937–0189) on or before July 28, 2000 to the Grants Management Specialist identified in the "Where to Obtain Additional Information" section of this announcement.

Deadline: Applications shall be considered as meeting the deadline if they are either:

(a) Received on or before the deadline date: or

(b) Sent on or before the deadline date and received in time for submission to the independent review group. (Applicants must request a legibly dated U.S. Postal Service postmark or obtain a legibly dated receipt from a commercial carrier or U.S. Postal Service. Private metered postmarks shall not be acceptable as proof of timely mailing.)

Late Applications: Applications which do not meet the criteria in (a) or (b) above are considered late applications, will not be considered, and will be returned to the applicant.

G. Evaluation Criteria

Each application will be evaluated individually against the stated criteria by an independent review group appointed by CDC. Evaluation Criteria instructions specific to each focus area may be found in Attachments 1–3.

H. Other Requirements

Technical Reporting Requirements: Provide CDC with an original plus two copies of:

- 1. Annual progress report, no more than 90 days after the end of the budget period:
- 2. Financial status report, no more than 90 days after the end of the budget period; and
- 3. Final financial and performance report, no more than 90 days after the end of the project period.

Send all reports to the Grants Management Specialist identified in the "Where to Obtain Additional Information" section of this announcement.

The following additional requirements are applicable to this announcement. For a complete description of each, See Attachment IV in the application kit.

AR-1 Human Subjects Requirements
AR-2 Requirements for Inclusion of
Women and Racial and Ethnic
Minorities in Research

AR-4 HIV/AIDS Confidentiality Provisions

AR–5 HIV Program Review Panel Requirements AR-7 Executive Order 12372 Review AR-9 Paperwork Reduction AR-10 Smoke-Free Workplace

Requirements

AR-11 Healthy People 2010

AR-12 Lobbying

I. Authority and Catalog of Federal Domestic Assistance Number

This program is authorized under section 317E of the Public Health Service Act, 42 U.S.C. section 42 U.S.C. 247b–6, as amended. The Catalog of Federal Domestic Assistance number is 93.947.

J. Where To Obtain Additional Information

This and other CDC Announcements can be found on the CDC homepage on the Internet address http://www.cdc.gov Click on "Funding" then "Grants and Cooperative Agreements".

To obtain additional information, contact: Carrie Clark, Grants
Management Specialist, Grants
Management Branch, Procurement and
Grants Office, Centers for Disease
Control and Prevention (CDC), 2920
Brandywine Road, Room 3000, Atlanta,
GA 30341–2783, Telephone (770) 488–
2783, E-mail address: zri4@cdc.gov

Programmatic technical assistance may be obtained from: Juanita Elder, Division of Tuberculosis Elimination, National Center for Prevention Services, Centers for Disease Control and Prevention (CDC), 1600 Clifton Road, NE., Mailstop E–10, Atlanta, GA 30333, Telephone (404) 639–8120, Email Address: jlc7@cdc.gov.

Dated: June 27, 2000.

John L. Williams,

Director, Procurement and Grants Office, Centers for Disease Control and Prevention (CDC).

[FR Doc. 00–16718 Filed 6–30–00; 8:45 am] BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Disease, Disability and Injury
Prevention and Control Special
Emphasis Panel: Fiscal Year 2000
Competitive Supplemental Funds for
Comprehensive STD Prevention
Systems: Monitoring Trends in STD
Prevalence, Tuberculosis, and HIV
Risk Behaviors Among Men Who Have
Sex With Men, PA# 99000-H

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the following meeting.

Name: Disease, Disability and Injury Prevention and Control Special Emphasis Panel: Fiscal Year 2000 Competitive Supplemental Funds for Comprehensive STD Prevention Systems: Monitoring Trends in STD Prevalence, Tuberculosis, and HIV Risk Behaviors among Men who have Sex with Men, PA# 99000–H.

Times and Dates: 8:30 a.m.–9 a.m., August 4, 2000 (Open), 9 a.m.–4:30 p.m., August 4, 2000 (Closed).

Place: Centers for Disease Control and Prevention, Corporate Square, Building 11, Conference Room 2214, Atlanta, Georgia 30329.

Status: Portions of the meeting will be closed to the public in accordance with provisions set forth in section 552b(c)(4) and (6), title 5 U.S.C., and the Determination of the Associate Director for Management and Operations, CDC, pursuant to Public Law 92–463

Matters to be Discussed: The meeting will include the review, discussion, and evaluation of applications received in response to Program Announcement 99000–H.

Contact Person for more Information: Beth Wolfe, Prevention Support Office, National Center for HIV, STD, and TB Prevention, CDC, Corporate Square Office Park, 11 Corporate Square Boulevard, M/S E07, Atlanta, Georgia 30329, telephone 404/639–8025, e-mail eow1@cdc.gov.

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

Dated: June 23, 2000.

Carolyn J. Russell,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).

[FR Doc. 00–16720 Filed 6–30–00; 8:45 am] BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Disease, Disability and Injury Prevention and Control Special Emphasis Panel: Community-Based Strategies To Increase HIV Testing of Persons at High Risk in Communities of Color, PA# 00100

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the following meeting.

Name: Disease, Disability and Injury Prevention and Control Special Emphasis